GPCR News & Events

Structure Therapeutics (GPCR) said its GLP-1 pill helped patients lose over 16% of their weight, on average, in a 10-month drug trial, Bill Alpert of Barron's writes. Weight loss continued the longer patients took the pill, with no plateau in sight, the company said. That's more weight loss than was achieved in studies of the Wegovy pill that Novo Nordisk (NVO) began marketing in January, or a pill that Eli Lilly (LLY) is expected to launch soon. The performance of Structure's pill may be good enough to make it an attractive takeover target for a larger pharmaceutical company looking to enter the drug industry's fastest-growing category, the author notes.

Structure Therapeutics announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity. This includes 44-week data from the Phase 2 ACCESS II study and interim data from the ongoing body composition study and the ACCESS open label extension study. Aleniglipron is an investigational orally-available, once-daily, nonpeptide small molecule agonist of the glucagon-like-peptide-1 receptor designed to address patient needs and accessibility. In the Phase 2 ACCESS II study, aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks. In the ACCESS OLE study, aleniglipron achieved continued weight loss from 36 weeks, up to 16.2% with 120 mg at 56 weeks. Both studies continue to demonstrate no evidence of weight loss plateau. Aleniglipron continues to demonstrate a tolerability profile that is consistent with the GLP-1 receptor agonist class and a compelling safety profile with no off-target events. In ACCESS II, across all active arms in participants who reached doses 120 mg or higher from 28 to 44 weeks, there was only one adverse event-related treatment discontinuation. With a median follow-up of 20 weeks, the tolerability data as of the February 20, 2026 cutoff date from the interim analyses of the OLE and the body composition studies provide further support that the use of 2.5 mg as a lower starting dose very meaningfully reduces the rate of AE-related discontinuations during the titration phase. In the OLE, with a median follow-up of 20 weeks, there was an overall AE-related discontinuation rate of 2%. In the body composition study, with a median follow-up of 20 weeks, there was an overall AE-related discontinuation rate of 3.4% in the aleniglipron arm. Together, these positive efficacy, tolerability and safety findings continue to support the advancement of aleniglipron into Phase 3 clinical development, with initiation anticipated in the second half of 2026.